Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 12/20 | 0.66 |
| ▸ | ACP1 | P24666 | 10/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31321767 | 0.93 | ALDH1A1 (0.64) | PTPN1ACP1ALDH1A1MEN1KMT2A | |
| SCHEMBL31321760 | 0.88 | ALDH1A1 (0.58) | PTPN1ACP1ALDH1A1MEN1KMT2A | |
| SCHEMBL31321765 | 0.88 | PTPN1 (0.66) | PTPN1ACP1ALDH1A1MEN1KMT2A | |
| SCHEMBL31321764 | 0.87 | ALDH1A1 (0.56) | PTPN1ACP1ALDH1A1MEN1KMT2A | |
| SCHEMBL31321768 | 0.87 | PTPN1 (0.67) | PTPN1ACP1ALDH1A1MEN1KMT2A | |
| SCHEMBL31321766 | 0.86 | PTPN1 (0.49) | PTPN1ACP1ALDH1A1MEN1KMT2A | |
| SCHEMBL31321761 | 0.83 | PTPN1 (0.57) | PTPN1ACP1ALDH1A1MEN1KMT2A | |
| SCHEMBL31321763 | 0.81 | ALDH1A1 (0.48) | PTPN1ACP1ALDH1A1MEN1KMT2A | |
| SCHEMBL31321758 | 0.80 | ALDH1A1 (0.55) | PTPN1ACP1ALDH1A1MEN1KMT2A | |
| SCHEMBL31321773 | 0.78 | PTPN1 (0.48) | PTPN1ACP1ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12145930-B1 | 4-thiazolidinone derivatives as EGFR inhibitors for anti-tumor activity | King Faisal University (SA) | 2024-11-19 | — | — | US | claimed |
| US-12145930-B1 | 4-thiazolidinone derivatives as EGFR inhibitors for anti-tumor activity | King Faisal University (SA) | 2024-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12145930-B1 | 4-thiazolidinone derivatives as EGFR inhibitors for anti-tumor activity | EGFR, ERBB4, ERBB2 | PTPN1 85/4885ACP1 373/4885ALDH1A1 1409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.